Some Senate Republicans See Gaetz Nomina...

Plus: Drugmaker Merck strikes a roughly $10 billion deal to buy Verona Pharma. The Justice Department’s criminal healthcare-fraud unit investigates UnitedHealth’s Medicare billing practices. And, shares in advertising conglomerate WPP tumble after it said clients were pulling bac ... Show More

Plus, Linda Yaccarino steps down as CEO of X after two years on the job. And U.S. measles cases hit a 33-year high. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices 

Plus: The U.S. seeks to ban China from buying American farmland. And a key architect of Apple’s supply chain will step down later this month. Luke Vargas hosts. Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices 

A.M. Edition for Nov. 20. WSJ China economics reporter Hannah Miao explains the preemptive steps companies reliant on Chinese imports are taking as they brace for a possible trade war between Washington and Beijing. Plus, Donald Trump picks Linda McMahon to lead the Education Dep ... Show More

P.M. Edition for Oct. 10. WSJ real estate reporter Kate King talks about reinventing grocery delivery with robotics. And WSJ economics reporter Harriet Torry on what the new U.S. inflation data mean for future interest-rate cuts. Plus, Donald Trump says he wants to make car-loan ... Show More

Bonus Episode for May 5. Consumers are in belt-tightening mode. Many are buying less, reconsidering their purchases and feeling rattled by volatile markets and the Trump administration’s shape-shifting tariff policies. For soda makers like Pepsi and restaurant chains like McDonal ... Show More

P.M. Edition for Oct. 8. WSJ markets reporter Hardika Singh discusses whether the third quarter earnings reports can show there’s more to the S&P 500 than just the Magnificent Seven. And WSJ’s Jared Hopkins explains what’s next for Pfizer after an activist investor revealed a $1 ... Show More

P.M. Edition for Feb. 7. China’s biotech industry is creating new drugs more cheaply and quickly than its U.S. counterparts. WSJ Heard on the Street columnist David Wainer tells us what’s behind the sector’s rise. Plus, new data show the U.S. economy added fewer jobs than expecte ... Show More

A.M. Edition for Feb. 12. WSJ columnist Spencer Jakab says a new twist on value investing is turning attention to companies returning gobs of cash to shareholders. But does that mean growth is dead? Plus, Elon Musk defends his government cost-cutting drive as President Trump hand ... Show More

Bonus Episode for April 29. Every U.S. manufacturer faces increased costs because of import tariffs and other countries’ countermeasures, but those making weapons have reason to be both worried and hopeful. WSJ Investing columnist Spencer Jakab discusses with WSJ reporter Sharon ... Show More

P.M. Edition for May 5. The Oracle of Omaha’s move after a 60-year run will be a moment of reckoning for the company he built. WSJ deputy markets editor Justin Baer discusses how Berkshire Hathaway’s new leadership will navigate that. Plus, a study out today shows that Beijing’s ... Show More